{
    "analysis_result": {
        "judgment": "不推荐的超适应症用药",
        "confidence": 0.9,
        "evidence_chain": {
            "drug_label": {
                "source": "奥氮平说明书",
                "version": "2024版",
                "evidence": [
                    "获批适应症：精神分裂症和双相情感障碍",
                    "未包含焦虑症相关适应症"
                ]
            },
            "clinical_guidelines": {
                "source": "中国焦虑障碍诊疗指南",
                "version": "2023版",
                "evidence": [
                    "轻度焦虑首选SSRI类药物",
                    "未推荐非典型抗精神病药物用于轻度焦虑"
                ]
            },
            "safety_analysis": {
                "source": "药物不良反应文献",
                "evidence": [
                    "长期使用可能导致代谢综合征",
                    "存在体重增加风险",
                    "可能出现嗜睡等不良反应"
                ]
            },
            "benefit_risk_analysis": {
                "conclusion": "风险大于获益",
                "evidence": [
                    "存在更安全有效的治疗选择",
                    "不良反应风险与症状程度不相称"
                ]
            }
        },
        "recommendations": [
            {
                "action": "建议调整用药方案",
                "alternatives": [
                    {
                        "drug_class": "SSRI",
                        "examples": ["舍曲林", "帕罗西汀"],
                        "evidence_level": "A",
                        "guideline_support": "中国焦虑障碍诊疗指南推荐的一线用药"
                    }
                ]
            }
        ]
    }
}
